What a Peptide Blend Is
A blend puts several lyophilized compounds in a single vial at fixed ratios, so one reconstitution delivers all of them at once. The convenience is obvious. The tradeoff is that the ratios are fixed: whatever the manufacturer chose is what you get, and the published research backing the combination is thinner than the research behind any single component.
Two blends dominate research discussions right now: GLOW and KLOW.
GLOW: 45 mg Total
The GLOW blend combines:
All three components have separate research histories in tissue repair. BPC-157 has extensive animal data on tendon, ligament, gut, and wound healing models. TB-500 (the thymosin beta-4 fragment) is studied for actin regulation and cell migration, processes central to tissue regeneration. GHK-Cu is the copper-binding tripeptide with four decades of published work on gene expression, wound contraction, and skin remodeling, which is why it is also a fixture in skincare research.
Notice the composition: GHK-Cu is the largest component by far at 30 of the 45 mg. Its inclusion reflects how much material the gene-expression research used, relative to the smaller amounts typical for BPC-157 and TB-500 in animal work.
KLOW: 80 mg Total
KLOW adds a fourth component:
KPV is the C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte-stimulating hormone). It carries the anti-inflammatory signaling activity of the parent hormone without the pigmentation effects, and it has been studied in intestinal epithelial inflammation models. The 50 mg allocation makes KPV the center of gravity in this blend, which tracks with the anti-inflammatory research focus that separates KLOW from GLOW.
What the Research Does and Doesn't Cover
Here is the part that matters most for interpreting blend research: the published literature covers the components separately. There are no published clinical trials of GLOW or KLOW as formulated combinations.
The blend rationale is component-wise. Each ingredient has its own animal or cell-culture literature, and the combination assumes those effects are compatible and roughly additive. That assumption is reasonable on mechanistic grounds, and it is also untested as a formulation. Anyone reading blend protocols should hold that distinction clearly: this is rational design on top of separate evidence, rather than evidence on the combination itself.
The Dosing Math Is Different
Blends also change the arithmetic. A 45 mg GLOW vial does not give you 45 mg of any one component. Working out the per-compound dose requires the ratio, the reconstitution volume, and the syringe units drawn, and the resulting per-component dose is usually well below what a standalone vial of that component would provide. The site's reconstitution calculator handles blend strength entries for exactly this reason.
Important Note
This article is for educational and research reference purposes only. The compounds discussed are sold for research purposes, and none of them have approved human therapeutic uses. Nothing here constitutes medical advice.